Etanercept for active Crohn’s disease: A randomized, double-blind, placebo-controlled trial

Gastroenterology

Volumn 121, Issue 5, 2001, Pages 1088-1094

  Sandborn, William J ^a   Hanauer, Stephen B ^b   Katz, Seymour ^c   Safdi, Michael ^d   Wolf, Douglas G ^e   Baerg, Richard D ^f   Tremaine, William J ^a   Johnson, Therese ^a   Diehl, Nancy N ^a   Zinsmeister, Alan R ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c Island Clinical Research Associates   (United States)

^d Consultants for Clinical Research ^*  (United States)

^e Atlanta Gastroenterology Associates   (United States)

^f Tacoma Digestive Disease Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; PLACEBO;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INJECTION SITE; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN DISEASE;

EID: 0034754477     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2001.28674     Document Type: Article

References (33)

1. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease
2. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease
3. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation
4. Tumour necrosis factor and Crohn's disease
5. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
6. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins
7. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor
8. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity
9. Isolation and characterization of a tumor necrosis factor binding protein from urine
10. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
11. Infliximab for the treatment of fistulas in patients with Crohn's disease
12. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
13. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
14. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
15. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
16. Infliximab and methotrexate in the treatment of rheumatoid arthritis
17. Long term safety of infliximab
18. Humanized antibodies
19. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists
20. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis
21. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
22. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
23. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
24. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
25. Etanercept (TNF recepter fusion protein, Enbrel) is effective and well tolerated in active refractory Crohn's disease: Results of a single center pilot trial
26. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study
27. Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease
28. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy
29. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease
30. An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
31. A randomized, double-blind, Placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease
32. The pharmacokinetics of etanercept in healthy volunteers